https://www.zacks.com/stock/news/2265491/here-s-what-key-metrics-tell-us-about-stryker-syk-q1-earnings?cid=CS-ZC-FT-fundamental_analysis|nfm-2265491
Apr 30, 2024 - The headline numbers for Stryker (SYK) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
zc:-6257502403438294247
0
https://www.zacks.com/stock/news/2261546/syk-vs-zbh-which-stock-looks-more-promising-ahead-of-q1-earnings?cid=CS-ZC-FT-analyst_blog|investment_ideas-2261546
Apr 24, 2024 - SYK and ZBH are expected to have witnessed strong procedural volume growth across the global market in the first quarter.
zc:-5652212222150047503
0
https://www.zacks.com/stock/news/2257016/henry-schein-hsic-global-presence-aids-macroeconomic-woes-stay?cid=CS-ZC-FT-analyst_blog|zer_report_update-2257016
Apr 17, 2024 - Henry Schein (HSIC) is busy promoting digital workflows for general dentistry and dental specialties.
zc:1822932812752351594
0
https://www.zacks.com/stock/news/2257026/here-s-why-you-should-retain-chemed-che-stock-for-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2257026
Apr 17, 2024 - Investors are optimistic about Chemed (CHE), backed by the strong performance of the VITAS Healthcare and Roto-Rooter segments.
zc:-5829071859321055349
0
https://www.zacks.com/stock/news/2256314/here-s-why-you-should-retain-charles-river-crl-stock-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2256314
Apr 16, 2024 - Investors are optimistic about Charles River (CRL) owing to strength in RMS and DSA segments.
zc:-5018326642776732823
0
https://www.zacks.com/stock/news/2254645/hologic-s-holx-new-launches-aid-macroeconomic-issues-ail?cid=CS-ZC-FT-analyst_blog|zer_report_update-2254645
Apr 12, 2024 - Hologic's (HOLX) Breast Health segment is gaining from a broad portfolio of solutions for breast cancer care, primarily in the burgeoning spaces of radiology, breast surgery, pathology and treatment.
zc:-6855190018735355026
0
https://www.zacks.com/stock/news/2253858/smith-nephew-snn-expands-in-australia-with-new-alliance?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2253858
Apr 11, 2024 - The latest partnership allows Smith+Nephew (SNN) to complement its existing implant range with the cutting-edge navigation technology of NAVBIT.
zc:-1261490857214792381
0
https://www.zacks.com/stock/news/2252692/here-s-why-you-should-retain-myriad-genetics-mygn-stock-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2252692
Apr 09, 2024 - Investors are optimistic about Myriad Genetics' (MYGN) strong solvency position and improvement in testing volume.
zc:-2930024978893210497
0
https://www.zacks.com/stock/news/2251992/abbott-abt-faces-low-testing-demand-currency-headwinds?cid=CS-ZC-FT-analyst_blog|zer_report_update-2251992
Apr 08, 2024 - Abbott's (ABT) core laboratory diagnostics business is gaining strength on the continued success of the Alinity suite of diagnostics instruments, along with a broad test menu offering.
zc:8036270438900298026
0
https://www.zacks.com/stock/news/2251935/im-cannabis-imcc-expands-business-in-germany-with-new-alliance?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2251935
Apr 08, 2024 - The partnership's core objective is to grant IM Cannabis' (IMCC) subsidiary, Adjupharm GmbH, exclusive rights to introduce Avant's BLK MKT cannabis brand in Germany's medical cannabis market.
zc:1916661488882171634
0